173 results about "Citrulline" patented technology

The invention relates to the technical field of nano-drugs, in particular to low-intensity focused ultrasound response nanoparticles for enhancing thrombus targeting and penetration, a preparation method of the nanoparticles and application of the nanoparticles in anti-thrombus treatment. The low-intensity focused ultrasound response nanoparticle for enhancing thrombus targeting and penetration comprises a platelet membrane shell, and a core is formed by wrapping perfluoropentane and L-arginine with polylactic acid-glycolic acid copolymer-polyethylene glycol. The platelet membrane ensures that the nanoparticles specifically target a thrombus part; under the stimulation of LIFU, the nanobubbles penetrate through the deep layer of thrombus, L-arginine is oxidized into L-citrulline, and nitric oxide is formed. Meanwhile, the LIFU triggers liquid-gas phase change and nitric oxide release, the ultrasonic cavitation effect is enhanced through the synergistic effect, thrombus structures including red blood cells, blood platelets and fibrin are specifically attacked, and efficient thrombolysis treatment is achieved. According to the technical scheme, the technical problem that the thrombolysis effect of ultrasonic nanoparticles is not ideal can be solved, and good clinical application prospects are achieved.

The invention discloses a rheumatoid arthritis diagnosis product and system and application thereof, and relates to the technical field of rheumatoid arthritis. The diagnostic marker comprises calcium, a ratio of arginine to ornithine, a ratio of phenylalanine to tyrosine, an anti-cyclic citrullinated peptide antibody and lysine. The invention provides a biomarker capable of accurately diagnosing rheumatoid arthritis RA, which comprises five indexes, namely calcium, the proportion of arginine to ornithine, the proportion of phenylalanine to tyrosine, an anti-cyclic citrullinated peptide antibody (anti-CCP) and lysine. The five indexes have the technical advantages of few indexes and excellent diagnosis performance. A diagnosis model constructed based on the five indexes has good sensitivity, specificity and accuracy. The kit can be used for diagnosis of rheumatoid arthritis.

The present invention relates to the fields of medicine and cosmetology, and discloses a cell active peptide composition that promotes the regeneration of multi-type collagen structural proteins, its preparation method, and its application in medicine and cosmetology. The composition uses raw materials such as tripeptide-10 citrulline, hexapeptide-9, hydrolyzed sodium hyaluronate, γ-aminobutyric acid, decarboxylated carnosine hydrochloride, acetyl tetrapeptide-3, acetyl tetrapeptide-11, palmitoyl dipeptide-7, and palmitoyl pentapeptide-4. The composition can promote the coordinated expression of skin type I, type III, type IV, type VII, type XVII collagen, fibronectin, elastin, and glycosaminoglycans; prevent collagen cross-linking, maintain triple helix structure, and inhibit collagen degradation. Applied to dermatology and cosmetology, it can accelerate the regeneration of structural proteins such as skin collagen, repair skin damage, reduce wrinkles such as crow's feet, tear groove lines, nasolabial folds, and under-eye lines, solve the skin aging problem caused by the loss of structural proteins such as collagen, and improve skin elasticity and firmness.

The invention discloses an efficient sparassis crispa bottle cultivation method, and belongs to the technical field of edible fungus cultivation. The bottle cultivation method comprises the steps of cultivation raw material preparation, compost preparation, fruiting bottle production, inoculation, fungus bottle culture, primordium induction and sporocarp culture. Specific fermentation raw materials are adopted to replace or partially replace pine sawdust to serve as cultivation main materials, humic acid, citrulline and arabinogalactan serve as additives, and efficient production of sparassis crispa is achieved in a bottle cultivation mode. According to the cultivation method, the primordium is easy to form, the consistency is good, the operation is simple, the biological conversion rate can reach 65-70%, and the growth and development period is 75-90 days.

The invention discloses a high-density ultrafine-particle-size copper-based catalyst as well as a preparation method and application thereof, and belongs to the technical field of catalysts. Nitrogen-doped carbon-coated copper nanoparticles are prepared through coordination of polyhydroxy glucose and citrulline with copper ions, drying and in-situ pyrolysis, so that the high-load, high-dispersion, high-density and ultrafine-particle-size copper-based catalyst is obtained. According to the method, growth and leaching of copper nanoparticles under the water phase reforming condition are effectively inhibited, and the hydrogen production performance of the catalyst is greatly enhanced. The catalyst has the advantages of high hydrogen production rate, high hydrogen selectivity and good hydrothermal stability. The high-density ultrafine-particle-size copper-based catalyst is especially suitable for catalyzing hydrogen production through ethanol water phase reforming, the hydrogen production rate reaches 33.8 micromol.gcat <-1 >. S <-1 > under the condition of 210 DEG C, the hydrogen selectivity is higher than 99.9%, and long-time efficient hydrogen production through ethanol water phase reforming is achieved.

The mixture as the micronutrient composition is a combination of alpha-ketoglutaric acid, nicotinamide or nicotinic acid, L-proline, L-glutamine, L-citrulline, sodium pyruvate, pantothenic acid, L-cysteine or N-acetylcysteine, magnesium malate, magnesium citrate, and methionine. The mixture is effective for the treatment of diseases due to oxidative stress. More specifically, the mixtures and cores as micronutrient compositions are effective in reversing saccharification in diabetes mellitus.

There is provided a method for diagnosing a subject with early onset muscle atrophy, said method comprising: obtaining a biosample from the subject; and assaying the biosample for one or more biomarkers, said one more biomarkers are taurine, proline, citrulline, trigonelline, thymidine, ornithine, glutamate, L-pyroglutamic acid, creatinine, adenine, nicotinamide, 2-methylhippuric acid, maltol, L-arginine, hypotaurine, L-glutamine, homogentisic acid, methylhistidine, oxoglutaric acid, xanthine, L-carnitine, succinate, or a combination thereof; and identifying the subject with early onset muscle atrophy on the basis of a deviation in the one or more of said one more biomarkers.

The embodiment of the invention discloses a composition with an anti-UVB damage function, a skin care product and application. The composition and the skin care product can be used for solving the anti-UVB damage problem. The composition comprises: a first compound selected from a compound represented by a formula (I) or a formula (II); and a second compound, wherein the second compound is selected from any one of palmitoyl tripeptide-5, acetyl dipeptide-1 cetyl ester, acetyl tripeptide-30 citrulline, and palmitoyl pentapeptide-4.

The invention discloses a carbamylated polypeptide and application thereof in preparation of a rheumatoid arthritis diagnostic kit. The invention provides a cyclization carbamylation polypeptide as shown in SEQ ID NO. 1 and SEQ ID NO. 2 or a combination of the cyclization carbamylation polypeptide and the combination of the cyclization carbamylation polypeptide and the combination. Tests prove that the cyclized carbamylation polypeptide antigens as shown in SEQ ID NO.1 and SEQ ID NO.2 independently have high diagnostic value for diagnosing the negative RA of the anti-cyclic citrullinated peptide antibody, and respectively have application prospects of being developed into diagnostic kits for the negative RA of the anti-cyclic citrullinated peptide antibody; the combination of SEQ ID NO.1 and SEQ ID NO.2 further improves the diagnosis value of the anti-cyclic citrullinated peptide protein antibody negative RA, and has the application prospect of being developed into the anti-cyclic citrullinated peptide protein antibody negative RA diagnosis kit in a combined manner.

The embodiment of the invention discloses a teprenone-containing composition, a skin care product and application. The teprenone-containing composition and the skin care product can promote the expression of CD44. The composition containing the teprenone is prepared from the teprenone and acetyl tripeptide-30 citrulline, and the mass ratio of the teprenone to the acetyl tripeptide-30 citrulline is 50 to (15 to 25).

The invention discloses an analysis method for determining multiple components of white spirit by high performance liquid chromatography-tandem mass spectrometry, and relates to the technical field of white spirit analysis and detection, and the analysis method comprises the following steps: firstly, preparing an ethyl carbamate precursor substance standard stock solution and a mixed standard intermediate solution, and diluting the mixed standard intermediate solution step by step to obtain a mixed standard working solution; then determining chromatographic and mass spectrometry conditions, wherein BEH Ami chromatographic column is adopted as the chromatographic condition, and 0.1% formic acid water-acetonitrile is adopted as a mobile phase for gradient elution; a mass spectrum condition adopts a multi-reaction monitoring mode under an electrospray positive ion mode; drawing a quantitative calibration curve; finally, preparing a to-be-detected sample for content determination. According to the analysis method for determining the multiple components of the Baijiu through the high performance liquid chromatography-tandem mass spectrometry, through chromatographic condition optimization and mass spectrometry parameter innovation, the detection efficiency is improved, peak area data of urea, citrulline and arginine can be synchronously obtained through single sample injection, the analysis time is short, and quantification is accurate.

The invention provides a wax gourd waste microbial organic fertilizer and a preparation method thereof. The wax gourd waste microbial organic fertilizer comprises 20-50 parts of a microbial flora combined enzyme yeast agent and 100-200 parts of a wax gourd waste organic fertilizer. White gourd wastes and waste chicken feathers are used as raw materials, so that white gourds are rich in citrulline and protein, the chicken feathers contain about 91% of keratin, 9.64% of nitrogen, 0.11% of phosphorus and 0.15% of potassium, and the fertilizer is an amino acid comprehensive fertilizer mainly containing nitrogen. The sugar mud contains various elements such as protein, sugar, calcium, iron, zinc and magnesium, the nutrient substances are fully kept and utilized through enzyme enzymolysis, nutrient absorption and growth of plants are promoted, and various microorganisms in the sugar mud are used for adjusting soil flora, improving the soil structure and improving the soil fertility; the saline-alkali content of the saline-alkali soil is improved, neutralized and corrected to reach the environment required by crop growth.

The micronutrient composition is a combination of at least 6 ingredients, for example alpha-Ketoglutaric Acid, Niacinamide and / or Niacin, L-Proline, L-Glutamine, L-Citrulline and Sodium Pyruvate, preferably at least 11 ingredients, for example alpha-Ketoglutaric Acid, Niacinamide and / or Niacin, L-Proline, L-Glutamine, L-Citrulline, Sodium Pyruvate, Pantothenic Acid, L-Cysteine and / or N-acetyl Cysteine, Magnesium Malate, Magnesium Citrate and Methionine, more preferably all of the ingredients which are selected from the group consisting of: alpha-Ketoglutaric Acid, Niacinamide and / or Niacin, L-Proline, L-Glutamine, L-Citrulline, Sodium Pyruvate, Pantothenic Acid, L-Cysteine and / or N-acetyl Cysteine, Magnesium Malate and / or Magnesium Citrate, Methionine and / or S- Adenosyl-Methionine (SAMe), Methylsulfonylmethane (MSM), and Wormwood powder and / or extract. The composition is effectively used to treat diseases due to oxidative stress. More specifically, the micronutrient composition is effective in reversing glycation in diabetes and thus in treating diabetes.

There is provided peptidic compounds of Formula I, A or B(Rradn6-[linker]-RL-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-ψ-Xaa9-NH2). Xaa1 is D-Phe, Cpa, D-Cpa, Nal, D-Nal, 2-Nal, or D-2-Nal; Xaa2 is Asn, Gln, Hse, Cit or His. Xaa3 is Trp, Bta, Trp(Me), Trp(7-Me), Trp(6-Me), Trp(5-Me), Trp(4-Me), Trp(2-Me), Trp(7-F), Trp(6-F), Trp(5-F), Trp(4-F), Trp(5-OH), or αMe-Trp. Xaa4 is Ala or Ser. Xaa5 is Val, Cpg, or Tle. Xaa6 is Gly, NMe-Gly, or D-Ala. Xaa7 is His or NMe-His. Xaa8 is Leu or Phe. Xaa9-NH2 is a C-terminally amidated amino acid residue selected from Pro, 4-oxa-L-Pro, Me2Thz, or Thz. ψ represents a peptide bond or reduced peptide bond joining Xaa8 to Xaa9. Rradn6 is 1-5 radiolabeling groups. There is also provided the use of such compounds as imaging agents or therapeutic agents.

A solid supplement composition comprising at least one non-ester nitrate compound and at least one isolated amino acid compound, wherein the at least one isolated amino acid compound is citrulline, wherein the at least one isolated amino acid compound is a separate compound than the at least one non-ester nitrate compound, and wherein the solid supplement composition comprises an amount of nitrate ion (NO3—) that is at least 0.33125 mg.

The invention discloses application of a marker in preparation of a sicca syndrome diagnosis product, and a construction method and equipment of a diagnosis model, and relates to the technical field of sicca syndrome diagnosis. The sicca syndrome marker comprises a ratio of citrulline to arginine. The ratio of citrulline to arginine in serum has a close relationship with sicca syndrome, a diagnostic model developed based on the marker has the technical advantages of high diagnostic specificity, high sensitivity and good accuracy, and the detection method is simple, convenient and reliable and is easy to clinically popularize.

The present invention relates to a Corynebacterium glutamicum mutant strain having increased L-citrulline productivity, and a method of producing L-citrulline using the same. The Corynebacterium glutamicum mutant strain is capable of producing L-citrulline in high yield and high concentration while inhibiting the production of by-products, because the activity of the protein that is expressed by the NCgl2657 gene therein has been weakened or inactivated.

The application provides an arginine deiminase mutant with alkali resistance, and the amino acid sequence of the mutant is SEQ ID NO:3. When L-arginine is used as a substrate to synthesize L-citrulline, the pH value of a reaction system can be as high as pH 11 or higher, and hydrochloric acid neutralization is not needed, so that the cost of product separation and purification and waste water treatment is significantly reduced.

The invention discloses a firming and anti-aging composition containing a Campania acuta bark extract and application of the firming and anti-aging composition, and belongs to the technical field of cosmetics. The firming and anti-aging composition containing the Campanumoea maculata bark extract comprises the following components: the Campanumoea maculata bark extract, a Flos Magnoliae Officinalis extract, a Tremella aurantialba extract and a composite polypeptide, and the composite polypeptide is composed of carnosine, acetyl tetrapeptide-5 and tripeptide-10 citrulline in a mass ratio of 1: (0.4-0.6): (0.2-0.6). Through the synergistic effect of the four components, the firming and anti-aging composition has a good effect of inhibiting the activity of elastase and collagenase.

The present disclosure relates to a composition for use in preventing and / or treating renal failure, such as uremia, in a subject. Said composition is a composition for oral consumption and comprises i) an extract of Rhodiola rosea root, ii) L-arginine, iii) L-citrulline; and iv) an extract of beet root. Said composition is also useful for preventing or reducing a gain of body weight, or for reducing body weight, in a subject in need thereof.

Provided herein is a methods for monitoring inflammatory disease activity in a subject comprising: (i) obtaining a sample from the subject; and (ii) measuring an autoantibody concentration in the sample using an immunoassay. Optionally, the inflammatory disease is rheumatoid arthritis (RA). Optionally, the autoantibody is an anti-citrullinated vimentin autoantibody (anti-Sa) or an anti-carbamylated protein autoantibody (anti-CarP). Optionally, the autoantibody concentration is correlated to a multi-disease biomarker activity (MBDA) score. Also provided herein are systems and kits for performing the method described herein.

To provide a composition for improving blood vessel repair function using cells.SOLUTION: This composition for improving blood vessel repair function comprises: at least one selected from the group consisting of astaxanthin, glucosamine hydrochloride, chondroitin sulfate, tocopherol, resveratrol, hesperidin (vitamin P), beta-carotene, ubiquinone, lipoic acid, zinc, arsine, arginine, citrulline, taurine, vitamin E, and mucin; and stem cells.SELECTED DRAWING: Figure 1

A heart boosting formulation comprises: L-carnitine, alpha-linolenic acid, citrulline, vitamin D3, lycopene, holy basil, cinnamon and beetroot.

To provide a new bitterness masking agent of potassium chloride, and to provide a production method or the like including the masking agent.SOLUTION: The bitterness masking agent of potassium chloride contains Balsam Peru essential oil as an active ingredient. Here, it is preferable to further contain at least one or more selected from the group consisting of arginine, glutamic acid, lysine and citrulline. It is also preferable to further contain at least one selected from the group consisting of acetoin, diacetyl, and 2, 3-pentanedione.SELECTED DRAWING: None

The present invention relates to citrullinated Cytokeratin peptides that can be used in cancer immunotherapy. The modified peptides may be used as vaccines or as targets for T cell receptor (TCR) and adoptive T cell transfer therapies. Such vaccines or targets may be used in the treatment of cancer.

To provide a citrulline-reducing agent for intraoral use.SOLUTION: The present invention provides a citrulline-reducing agent for intraoral use that contains vitamin B6. The citrulline-reducing agent for intraoral use inhibits citrulline production and / or secretion by intraoral bacteria such as those belonging to Porphyromonas, Fusobacterium, Prevotella, Veillonella, Treponema, or Streptococcus.SELECTED DRAWING: None

The invention discloses a promethazine hydrochloride injection and a preparation method thereof, and relates to the technical field of pharmaceutical preparations. Every 1 mL of the promethazine hydrochloride injection is prepared from the following raw materials and auxiliary materials: 20 to 30 mg of promethazine hydrochloride, 0.3 to 0.8 mg of anhydrous sodium sulfite, 0.5 to 1.5 mg of sodium pyrosulfite, 0.02 to 0.08 mg of citrulline, 0.02 to 0.05 mg of gallic acid and the balance of water for injection. The stability of the promethazine hydrochloride injection can be improved, the impurity content can be reduced, and it can be guaranteed that bacterial endotoxin meets the production requirement in the long-term storage process.

The invention relates to a set of diagnostic markers comprising glutamic acid, glutamine, glycine, tryptophan, proline, threonine, citrulline, aspartic acid, and asparagine, for use in diagnosing breast cancer, and to an in vitro method for diagnosing breast cancer.

The present invention provides an antibody or a conjugated fragment of a citrulline-containing epitope used for the treatment or prevention of diseases associated with the release of extracellular traps from cells, such as neutrophil extracellular trap (NET)-associated pathology (NET-associated pathology) or eosinophil extracellular trap (EET)-associated pathology (EET-associated pathology), and provides a method comprising administering at least one dose of the antibody at a specific concentration. The present invention also provides the method itself. NET-related pathologies include systemic lupus erythematosus (SLE), lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus exacerbated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, or wound healing in diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in This includes other NET-related pathologies, such as the health of transplanted organs in vivo or ex vivo.The present invention also relates to wound healing in SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid antibody syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia asthma, allergic rhinovirus exacerbating asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, or diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in vivo or ex vivo The present invention provides pharmaceutical compositions and methods for treating and preventing NET-related pathologies, including other NET-related pathologies such as the health of transplanted organs in vivo. NET-related pathologies include eosinophilic diseases or conditions of the skin, respiratory eosinophilic diseases or conditions, gastrointestinal eosinophilic diseases or conditions, allergic diseases or conditions, or eosinophilic diseases or conditions such as helminthic, fungal, viral or bacterial infections.

The invention provides application of lactobacillus reuteri to improvement of prostatitis and erectile dysfunction. The bacterial strain is lactobacillus reuteri NHNK-2001, the lactobacillus reuteri NHNK-2001 is preserved in the China Center for Type Culture Collection on April 25, 2024, and the preservation number of the lactobacillus reuteri NHNK-2001 is CCTCC (China Center for Type Culture Collection) NO: M 2024800. The NHNK-2001 has the functions of generating L-citrulline, repairing aged vascular endothelial cells, promoting vasodilation, repairing aged prostate cells and reducing prostatitis, and can be used for preparing products for improving prostatitis and erectile dysfunction.